Compare RKT & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RKT | ARGX |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1B | 52.6B |
| IPO Year | 2020 | 2017 |
| Metric | RKT | ARGX |
|---|---|---|
| Price | $19.49 | $846.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $19.46 | ★ $971.89 |
| AVG Volume (30 Days) | ★ 18.2M | 300.0K |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 23.27 |
| Revenue | ★ $6,098,944,000.00 | $3,683,281,000.00 |
| Revenue This Year | $15.19 | $91.44 |
| Revenue Next Year | $71.65 | $36.90 |
| P/E Ratio | ★ N/A | $33.78 |
| Revenue Growth | 41.68 | ★ 92.98 |
| 52 Week Low | $10.06 | $510.06 |
| 52 Week High | $22.56 | $934.62 |
| Indicator | RKT | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 39.21 |
| Support Level | $18.71 | $843.03 |
| Resistance Level | $19.63 | $858.80 |
| Average True Range (ATR) | 0.58 | 15.73 |
| MACD | 0.00 | -5.90 |
| Stochastic Oscillator | 77.27 | 21.13 |
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and will also be the largest mortgage servicer in the US following its acquisition of the Mr. Cooper Group.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.